Şunu aradınız:: tigeciklin (Slovence - İngilizce)

tigeciklin
tigecycline

tygacil tigeciklin
tygacil tigecycline

zdravilna učinkovina je tigeciklin.
the active substance is tigecycline.

vsebuje zdravilno učinkovino tigeciklin.
it contains the active substance tigecycline.

tycagil vsebuje zdravilno učinkovino tigeciklin.
tygacil contains the active substance tigecycline.

na splošno velja, da je tigeciklin bakteriostatik.
in general, tigecycline is considered bacteriostatic.

tigeciklin pri podganah in kuncih ni bil teratogen.
tigecycline was not teratogenic in the rat or rabbit.

tygacil 50 mg prašek za raztopino za infundiranje tigeciklin
tygacil 50 mg powder for solution for infusion tigecycline

tigeciklin se s hemodializo ne odstrani v pomembnih količinah.
tigecycline is not removed in significant quantities by haemodialysis.

na podlagi in vitro študije je tigeciklin substrat p-gp.
based on an in vitro study tigecycline is a p-gp substrate.

tigeciklin se daje intravensko in ima zato 100-odstotno biološko uporabnost.
tigecycline is administered intravenously and therefore has 100 % bioavailability.

ni znano, ali se tigeciklin/presnovki izločajo v materino mleko.
it is unknown whether tigecycline/metabolites are excreted in human milk.

absorpcija tigeciklin se daje intravensko in ima zato 100- odstotno biološko uporabnost.
tigecycline is administered intravenously and therefore has 100% bioavailability.

tigeciklin lahko povzroča neželene učinke, ki so podobni kot pri antibiotikih tetraciklinske skupine.
tigecycline may have adverse reactions similar to tetracycline class antibiotics.

zaželeno je, da se tigeciklin pri pediatričnih bolnikih daje z infuzijo, ki traja 60 minut.
tigecycline should be preferably administered over a 60-minute length of infusion in paediatric patients.

farmakokinetične študije na živalih in ljudeh so pokazale, da se tigeciklin z lahkoto porazdeljuje v tkiva.
animal and human pharmacokinetic studies have demonstrated that tigecycline readily distributes to tissues.

rezultati študij na živalih kažejo, da tigeciklin prehaja skozi posteljico in ga najdemo v plodovih tkivih.
results of animal studies indicate that tigecycline crosses the placenta and is found in foetal tissues.

tigeciklin deluje tako, da blokira ribosome bakterij oziroma tiste dele bakterijskih celic, ki proizvajajo nove beljakovine.
tigecycline works by blocking the bacteria’ s ribosomes, the parts of the bacterial cells where new proteins are made.

zdravilna učinkovina zdravila tygacil, tigeciklin, spada v skupino antibiotikov, imenovanih „glicilciklini“.
the active substance in tygacil, tigecycline, belongs to a group of antibiotics called ‘glycylcyclines’.

in vitro tigeciklin ni niti kompetitiven inhibitor niti ireverzibilen inhibitor encimov cyp450 (glejte poglavje 5.2).
in vitro, tigecycline is neither a competitive inhibitor nor an irreversible inhibitor of cyp450 enzymes (see section 5.2).